What is William Blair’s Forecast for Biodesix Q1 Earnings?

Biodesix, Inc. (NASDAQ:BDSX) – Stock analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Biodesix in a report issued on Tuesday, March 4th. William Blair analyst A. Brackmann anticipates that the company will post earnings per share of ($0.08) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($0.35) per share. William Blair also issued estimates for Biodesix’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($0.22) EPS.

Biodesix Trading Up 1.4 %

Shares of NASDAQ BDSX opened at $0.86 on Thursday. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The business has a fifty day simple moving average of $1.08 and a two-hundred day simple moving average of $1.40. The firm has a market cap of $125.42 million, a PE ratio of -2.21 and a beta of 1.10. Biodesix has a twelve month low of $0.64 and a twelve month high of $2.04.

Biodesix (NASDAQ:BDSX) last issued its earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $20.43 million during the quarter, compared to analyst estimates of $19.92 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%.

Insider Buying and Selling at Biodesix

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of Biodesix stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at $645,791.24. The trade was a 10.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 128,702 shares of company stock valued at $118,406 in the last ninety days. Corporate insiders own 69.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BDSX. Wilmington Savings Fund Society FSB purchased a new position in shares of Biodesix in the 3rd quarter valued at $10,849,000. Samjo Management LLC purchased a new position in shares of Biodesix in the 4th quarter valued at $3,790,000. Susquehanna International Group LLP increased its holdings in shares of Biodesix by 769.8% in the 4th quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company’s stock valued at $1,707,000 after acquiring an additional 987,475 shares during the period. Silverarc Capital Management LLC increased its holdings in shares of Biodesix by 21.7% in the 4th quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock valued at $6,628,000 after acquiring an additional 771,187 shares during the period. Finally, AIGH Capital Management LLC increased its holdings in shares of Biodesix by 8.8% in the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock valued at $9,455,000 after acquiring an additional 500,000 shares during the period. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.